Cross-sectional study of reversible airway obstruction in LAM: better evidence is needed for bronchodilator and inhaled steroid use.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 31363020.
- Also identified by DOI 10.1136/thoraxjnl-2019-213338.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lymphangioleiomyomatosis can be associated with reversible airflow obstruction and although no guidelines around reversibility testing or inhaled therapy exist, many patients receive bronchodilators and inhaled corticosteroids. To better identify those who may benefit, we examined bronchodilator reversibility and inhaled therapy in a national cohort of 213 subjects. 20% of those tested had airway reversibility by standard criteria. 55% of patients used 13 different combinations of bronchodilators and inhaled corticosteroids. Increasing inhaler classes were associated with reversibility and more rapid FEV<sub>1</sub> decline. Reversibility testing should be performed in all patients and inhaled therapy should be formally studied.
Medical subject headings
- Airway Obstruction
- Albuterol
- Forced Expiratory Volume
- Glucocorticoids
- Lung
- Lung Neoplasms
- Lymphangioleiomyomatosis